Corbus Pharmaceuticals Holdings Inc Aktie News

NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced it will be participating in the following investor conferences.

Corbus Pharmaceuticals is continuing to march forward with their Nectin-4 ADC, with recent data showcasing impressive tolerability in particular. A recent fundraising for around $75 million was a strong negative catalyst, but it puts their runway right for now. Strong upside potential is here, but there are serious risks in jumping in to an early-phase company.

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchas...

NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. A...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP ) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel October 19, 2025 4:00 AM EDT Company Participants Yuval Cohen - CEO & Director Dominic Smethurst - Chief Medical Officer Conference Call Participants Cesar Augusto Perez Batista Ari Rosenberg Glenn J. Hanna Tsan-Yu Hsieh - William Blair & Company L.L.C.

NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company') today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poster at the 2025 European Society for Medical Oncology (ESMO25) Congress being held in Berlin, Germany. The poster titled, “Phase 1/2 study of the next-generation Ne...

NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously trea...

Corbus (CRBP) Q2 Loss Beats Estimates